Pfizer Inc. (NYSE:PFE) announced today it will present the results of a
Phase 2, randomized study to evaluate co-administration of the company’s
investigational meningococcal group B vaccine, bivalent recombinant
LP2086 (rLP2086), with a licensed quadrivalent human papillomavirus
vaccine (HPV4), at IDWeek 2014™ in Philadelphia.
for Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine investment picks